文献速递血栓与止血

VOYAGER PAD试验:下肢血运重建后症状性外周动脉疾病患者动脉与静脉血栓事件的预防——双联抗凝/抗血小板方案对比单用抗血小板治疗

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
PubMed 文献 · J Thromb Haemost · 2022-03-07

VOYAGER PAD随机纳入6564例接受下肢血运重建的症状性外周动脉疾病患者,比较利伐沙班2.5 mg每日两次联合阿司匹林与安慰剂联合阿司匹林。中位随访2.5年,利伐沙班联合阿司匹林将首次和总动脉与静脉血栓事件分别降至5.4和7.9事件/100患者年,总血栓事件较阿司匹林降低23%(HR 0.77,95%CI 0.67-0.89,P=0.0005)。

要点

  • 利伐沙班2.5 mg每日两次联合阿司匹林降低下肢血运重建后总血栓事件(HR 0.77,95%CI 0.67-0.89)。
  • 安慰剂组首次和总血栓事件率分别为7.1和10.3事件/100患者年。
  • 利伐沙班联合阿司匹林组首次和总血栓事件率分别为5.4和7.9事件/100患者年。

核心结论

  • 评估总动脉与静脉血栓事件而非仅首次事件,能更全面反映疾病负担和治疗绝对获益。
  • 下肢血运重建后,审慎调节多条凝血通路可能比强化抑制单一止血系统成分提供更广泛获益。

研究设计与样本

  • VOYAGER PAD随机纳入6564例接受下肢血运重建的症状性外周动脉疾病患者,比较利伐沙班2.5 mg每日两次与安慰剂,均以阿司匹林为背景治疗。
  • 采用边际比例风险模型计算首次和总事件的治疗风险比及95%CI,非血栓性死亡作为竞争性终末事件处理。
  • 发生率按每100患者年随访的事件数计算,中位随访2.5年。

主要发现

  • 安慰剂组首次和总血栓事件率分别为7.1和10.3事件/100患者年。
  • 总血栓事件中动脉占95%、静脉占5%,三分之二(925/1372)为非致命首次事件。
  • 近三分之一首次事件患者发生第二次动脉或静脉血栓事件。
  • 利伐沙班联合阿司匹林组首次和总血栓事件率分别为5.4和7.9事件/100患者年,总血栓事件较阿司匹林降低23%(HR 0.77,95%CI 0.67-0.89,P=0.0005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular disease burden after lower extremity revascularization (LER) comprises more than the first event, more vascular beds than the local arteries, and more than one clinical event type. OBJECTIVES: Assess total arterial and venous thrombotic burden after LER for symptomatic peripheral artery disease (PAD) and effect of low-dose anticoagulation added to low-dose antiplatelet therapy. PATIENTS/METHODS: VOYAGER PAD randomized 6564 symptomatic PAD patients undergoing LER to rivaroxaban 2.5 mg twice-daily or placebo on aspirin background. Marginal proportional-hazards models used to generate treatment hazard ratios and associated 95% CIs for first and total events; non-thrombotic deaths treated as competing terminal events. Incidence rates calculated as number of events per 100 patient-years follow-up. RESULTS: Over 2.5 years (median), first and total thrombotic event rates: 7.1 and 10.3 events/100 patient-years, respectively, in placebo group. Two-thirds (925/1372) of total thrombotic events (arterial 95%, venous 5%) were nonfatal first events. Nearly one-third of patients with first event had a second arterial or venous thrombotic event. Rivaroxaban plus aspirin reduced first and total arterial and venous thrombotic events to 5.4 and 7.9 events/100 patient-years, respectively, a reduction in total thrombotic events over aspirin of 23% (HR: 0.77, 95%CI: 0.67-0.89, p = .0005), preventing 6.1 total arterial and venous thrombotic events at 3 years. CONCLUSIONS: Assessing total arterial and venous thrombotic events, not just first events, provides more complete information about disease burden and absolute on-treatment impact. Following LER, judicious modulation of more than one coagulation pathway can provide broader benefit than intensifying inhibition of one hemostatic system component.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Berkowitz SD, Bauersachs RM, Szarek M, et al. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. J Thromb Haemost. 2022. PMID: 35170216. doi:10.1111/jth.15673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。